AstraZeneca says prospect of COVID-19 drug success underscores value of vaccine ops

An AstraZeneca executive said the prospect of offering a new treatment to prevent COVID-19 could position the British drugmaker as a supplier of both vaccines and drugs which guard against the infectious disease. The remarks by executive Mene Pangalos on Friday, after antibody drug AZD7442 was shown to prevent COVID-19 in a trial, came after another leading executive, Ruud Dobber, said last month that different options were being explored for the vaccine operations, which stem from a collaboration with Oxford University